CVRx, Inc. (NASDAQ:CVRX) Receives $17.83 Average Price Target from Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX) have been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $17.83.

Several research analysts have recently weighed in on the stock. Craig Hallum boosted their price objective on shares of CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. William Blair upgraded shares of CVRx from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 14th. Piper Sandler boosted their price objective on shares of CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 5th. Finally, Canaccord Genuity Group boosted their price objective on shares of CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, February 5th.

Institutional Trading of CVRx

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its holdings in shares of CVRx by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company’s stock worth $49,000 after acquiring an additional 1,186 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of CVRx by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company’s stock worth $385,000 after acquiring an additional 1,296 shares during the period. Barclays PLC lifted its holdings in shares of CVRx by 12.1% during the 4th quarter. Barclays PLC now owns 21,378 shares of the company’s stock worth $270,000 after acquiring an additional 2,311 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of CVRx by 86.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,894 shares of the company’s stock worth $113,000 after acquiring an additional 4,115 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of CVRx by 36.1% during the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after acquiring an additional 5,053 shares during the period. Institutional investors own 75.27% of the company’s stock.

CVRx Trading Down 4.7 %

Shares of NASDAQ:CVRX opened at $12.35 on Tuesday. The company’s 50-day moving average price is $14.89 and its two-hundred day moving average price is $12.43. The company has a debt-to-equity ratio of 0.69, a current ratio of 12.06 and a quick ratio of 10.23. CVRx has a one year low of $6.40 and a one year high of $22.45. The stock has a market capitalization of $321.54 million, a PE ratio of -4.59 and a beta of 1.30.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. On average, equities analysts forecast that CVRx will post -1.91 EPS for the current fiscal year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.